<div id="readability-page-1"><div id="article-body-row"> <div> After a 2024 in which AbbVie’s Skyrizi boasted the highest TV drug ad spending outlay on seven of our monthly roundups—and took second place in four more—the immunology med has seen that dominance slip in 2025. Skyrizi dropped to fourth place in the monthly rankings in January and March, and climbed to second in February. It wasn’t until last month that the blockbuster drug finally reclaimed the TV ad spending throne: According to iSpot.TV, its total outlay reached $34.7 million in April, up from just under $28 million the month before. That sent Novo Nordisk’s Wegovy—March’s No. 1 spender—down to the second spot, as its spending fell from more than $40 million in March to $31.6 million in April. Close behind was AbbVie’s Rinvoq, which has historically stuck close to its sibling Skyrizi in the monthly rankings, with $29 million spent airing its commercials last month. Filling out the middle of April’s list were several familiar standbys. Johnson &amp; Johnson’s Tremfya slipped two spots from the previous month to take fourth place, while Lundbeck and Otsuka’s Rexulti held steady at fifth. In sixth and seventh, Sanofi and Regeneron’s Dupixent switched spots with Novo’s Ozempic from March’s standings, as Dupixent’s monthly spending ticked upward by more than $3 million and Ozempic’s dropped about the same amount month over month. AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a $16.5 million outlay. Eli Lilly and Boehringer Ingelheim’s Jardiance, meanwhile, held steady in ninth. Rounding out the list was Intra-Cellular’s schizophrenia and bipolar depression drug Caplyta, which hasn’t shown up on a monthly top 10 list since January. Noticeably absent from April’s list of top spenders was Novartis’ Pluvicto, which led the ranking in January and snagged the No. 7 spot for the whole first quarter. Lilly’s Zepbound, too, made the quarterly list—in the 10th position—and took eighth in March, but failed to chart in April. Overall, TV ad spending across the top 10 drug brands held relatively steady in April. They spent a combined $233.6 million airing their commercials, only a slight drop from March’s $248 million total, and still well above February’s $204.5 million. Below, find the full data for April’s 10 biggest pharma ad spenders, as compiled by iSpot.TV. 1. Skyrizi Movement: Up three spots What is it? AbbVie’s immunology drug Est. national TV ad spend: $34.7 million (up from $27.9 million in March) Number of spots: Six (four psoriasis, one Crohn’s/UC, one psoriatic arthritis) Biggest-ticket ad: “In the Picture” (est. $20 million) 2. Wegovy Movement: Down one spot What is it? Novo Nordisk’s GLP-1 agonist for obesity Est. national TV ad spend: $31.6 million (down from $40.4 million in March) Number of spots: One Biggest-ticket ad: “Discover the Power: $0” (est. $40.4 million) 3. Rinvoq Movement: No change What is it? AbbVie’s JAKi immunology drug Est. national TV ad spend: $29 million (down from $29.2 million in March) Number of spots: Five (two eczema, two UC/Crohn’s, one arthritis) Biggest-ticket ad: “Just Okay: Jet Ski” (est. $9.4 million) 4. Tremfya Movement: Down two spots What is it? Johnson &amp; Johnson’s immunology drug Est. national TV ad spend: $28.6 million (down from $32.6 million in March) Number of spots: Five (four psoriasis, one ulcerative colitis) Biggest-ticket ad: “Break Away” (est. $17.6 million) 5. Rexulti Movement: No change What is it? Lundbeck and Otsuka’s neurology drug Est. national TV ad spend: $25.4 million (down from $26.2 million in March) Number of spots: Two (one depression, one Alzheimer’s) Biggest-ticket ad: “Still Masking: Garage and Office” (est. $12.8 million) 6. Dupixent Movement: Up one spot What is it? Sanofi and Regeneron’s immunology drug Est. national TV ad spend: $24.3 million (up from $20.9 million in March) Number of spots: Seven (three asthma, four eczema) Biggest-ticket ad: “Kenny” (est. $10.3 million) 7. Ozempic Movement: Down one spot What is it? Novo Nordisk’s GLP-1 agonist for diabetes Est. national TV ad spend: $18.2 million (down from $21.7 million in March) Number of spots: Two Biggest-ticket ad: “Testimonials: Michael and Tanya” (est. $10.2 million) 8. Vraylar Movement: Up two spots What is it? AbbVie’s bipolar and MDD drug Est. national TV ad spend: $16.5 million (up from $14.3 million in March) Number of spots: Two (one depression, one bipolar) Biggest-ticket ad: “Stuck in My Head: Basketball” (est. $12.7 million) 9. Jardiance Movement: No change What is it? Eli Lilly and Boehringer Ingelheim’s diabetes and kidney disease drug Est. national TV ad spend: $16.4 million (up from $15.8 million in March) Number of spots: Three (one CKD, two diabetes) Biggest-ticket ad: “Musical: Baseball” (est. $7.8 million) 10. Caplyta Movement: Not listed last month What is it? Intra-Cellular’s schizophrenia and bipolar depression drug Est. national TV ad spend: $8.9 million (down from $9.3 million in March) Number of spots: Two Biggest-ticket ad: “The Darkness of Bipolar Depression: Let in The Lyte” (est. $4.7 million) </div> </div></div>

ABBV

AbbVie’s Skyrizi regained the top spot in TV ad spending for April, with an outlay of $34.7 million, up from $27.9 million in March. Novo Nordisk’s Wegovy fell to second place, spending $31.6 million, down from over $40 million. AbbVie’s Rinvoq maintained third place with $29 million. Overall, the top 10 drug brands spent a combined $233.6 million on TV ads in April, a slight decrease from March's $248 million. Other notable spenders included Johnson & Johnson’s Tremfya and Lundbeck’s Rexulti.

AbbVie’s Skyrizi retakes top TV ad spending spot in April